Zobrazeno 1 - 10
of 53
pro vyhledávání: '"VAM Funke"'
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 45, Iss , Pp S211- (2023)
The use of tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of chronic myeloid leukemia (CML), making it possible for patients to have a life expectancy similar to that of the healthy population. To improve treatment adherence and
Externí odkaz:
https://doaj.org/article/661e09fe3447409d9eb40ee17428f4f3
Autor:
AP Azambuja, Y Schluga, JLP Justus, MP Beltrame, M Malvezzi, VAM Funke, R Pasquini, CMS Bonfim
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 45, Iss , Pp S316- (2023)
Introduction: Minimal residual disease (MRD) detected before and after hematopoietic stem cell transplantation (HSCT) is associated with poor outcomes in high-risk acute leukemia. This study prospectively evaluates the impact of MRD accessed by multi
Externí odkaz:
https://doaj.org/article/b38ac27fc7a84961ba68d5a31af41c45
Autor:
GRO Medeiros, ACM Lima, I Menezes, DC Setubal, CBDS Sola, R Marchesini, SK Nabhan, ALV Mion, R Pasquini, VAM Funke
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 45, Iss , Pp S546-S547 (2023)
Introdução: O surgimento dos Inibidores de Tirosino-Quinase (ITQ), no final da década de 90, revolucionou o tratamento dos pacientes com Leucemia Mieloide Crônica (LMC), impactando diretamente na sobrevida desta população nas últimas duas déc
Externí odkaz:
https://doaj.org/article/7da999868b0349129e2213e73426aed5
Autor:
R Marchesini, I Colturato, RR Muratori, VAM Funke, SK Nabhan, G Loth, FR Barbieri, ERP Delattre, ACM Lima, C Bonfim
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 45, Iss , Pp S548-S549 (2023)
Introduction/objectives: Severe Aplastic Anemia (SAA) is the most frequent indication for Hematopoietic Cell Transplantation (HCT) for nonmalignant diseases in Brazil. Survival after HCT from HLA-Matched Related (MRD), HLA-Matched Unrelated (MUD), an
Externí odkaz:
https://doaj.org/article/8a21f323152b4044b0ac0a2c2378ec6a
Autor:
RS Tavares, NCD Clementino, MRM Conchon, KBB Pagnano, SA Santana, ACKVD Nascimento, VAM Funke, RT Centrone, FS Seguro, JAP Bortolini, DA Silveira, I Bendit
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 43, Iss , Pp S128- (2021)
Introduction: Myelofibrosis (MF) is the most severe myeloproliferative neoplasia (MPN), with a very variable survival, which can be beyond 20 years to less than two years. The only curative treatment is allogeneic bone marrow transplantation (ABMT),
Externí odkaz:
https://doaj.org/article/ffe4befaeb214d519b8c495aedf5e32f
Autor:
MD Marquetti, LF Soares, GA Moreira, JS Lima, TDS Baldanzi, AVCDS Gasparine, MC Guedes, LMC Borges, R Galli, VAM Funke
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 43, Iss , Pp S131- (2021)
Descrição do caso: Paciente feminina, 26 anos, caixa de mercado. Encaminhada em setembro de 2020 por hematologista externo para avaliação de leucocitose e trombocitose progressivas pós-esplenectomia. Histórico de diagnóstico de Púrpura Trombo
Externí odkaz:
https://doaj.org/article/2b4b6faa338b4cc897880643a9391e41
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 43, Iss , Pp S133-S134 (2021)
G. C. B., masculino, 30 anos. Diagnóstico de Leucemia Mieloide Crônica (LMC) em fase crônica em 2015, com início de tratamento com imatinibe na ocasião, alcançando resposta molecular maior (RMM) aos 6 meses de tratamento, com BCR-ABL 0,084%. No
Externí odkaz:
https://doaj.org/article/0c83907c62a44b48ab44949489870ef6
Autor:
VAM Funke, ACM Lima, N Hamerschlak, V Colturato, MP Souza, AC Vigorito, GM Teixeira, VG Rocha, LCB Mariano, D Lerner, GMN Barros, R Pasquini, AA Paz, HRA Neves, AJ Simioni, CC Silva, V Martins, CL Voltarelli, BC Tan, ME Flowers
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 43, Iss , Pp S246-S247 (2021)
Background: Allogeneic hematopoietic stem cell transplantation (allo-SCT) is a well-established treatment modality for myelofibrosis (MF) and the only potentially curative treatment. However, adequate engraftment, relapse and transplant related morta
Externí odkaz:
https://doaj.org/article/0c7c191759b44a209910548b4d30b7ae
Autor:
LG Silva, I Menezes, MC Gallucci, CB Sola, DC Setubal, SK Nabhan, MM Oliveira, R Pasquini, VAM Funke
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 43, Iss , Pp S247- (2021)
Introdução: A recidiva após TCTH alogênico é observada em 20% a 40% dos pacientescom LMC. A monitorização dos níveis de BCR-ABL1 é uma forma de detecção precocede recaída após TCTH. No entanto, a sensibilidade da tecnologia de PCR aument
Externí odkaz:
https://doaj.org/article/c9728edde0c647c585e1674d15c5274e
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 43, Iss , Pp S270- (2021)
Introdução: a doença do enxerto versus hospedeiro (DECH) agudo ou crônico, é uma das principais complicações após o transplante de medula óssea ocorrendo entre 40-50% dos pacientes. Apesar de representar um fator de morbimortalidade relacion
Externí odkaz:
https://doaj.org/article/4cc088c157914014b223fd4049fa3004